Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
ValGenesis Wraps Up Global ValConnect Innovation Day Series with Hyderabad Event [Yahoo! Finance]
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript [Seeking Alpha]
Dr. Reddy's Laboratories (NYSE:RDY) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.